Global Long-Acting Insulin Analogue Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Long-Acting Insulin Analogue market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Long-Acting Insulin Analogue include Tonghua Dongbao Pharmaceutical, Sanofi, Novo Nordisk, The United Laboratories International Holdings, Eli Lilly and Company and Gan and Lee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Long-Acting Insulin Analogue, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Long-Acting Insulin Analogue, also provides the sales of main regions and countries. Of the upcoming market potential for Long-Acting Insulin Analogue, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Long-Acting Insulin Analogue sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-Acting Insulin Analogue market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Long-Acting Insulin Analogue sales, projected growth trends, production technology, application and end-user industry.
Long-Acting Insulin Analogue Segment by Company
Tonghua Dongbao Pharmaceutical
Sanofi
Novo Nordisk
The United Laboratories International Holdings
Eli Lilly and Company
Gan and Lee Pharmaceuticals
Long-Acting Insulin Analogue Segment by Type
Insulin Degludec
Insulin Detemir
Insulin Glargine
Long-Acting Insulin Analogue Segment by Application
Gestational Diabetes
Type 2 Diabetes
Type 1 Diabetes
Other Diabetes
Long-Acting Insulin Analogue Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-Acting Insulin Analogue market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-Acting Insulin Analogue and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-Acting Insulin Analogue.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Long-Acting Insulin Analogue market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Insulin Analogue manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-Acting Insulin Analogue in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Long-Acting Insulin Analogue in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
According to APO Research, The global Long-Acting Insulin Analogue market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Long-Acting Insulin Analogue include Tonghua Dongbao Pharmaceutical, Sanofi, Novo Nordisk, The United Laboratories International Holdings, Eli Lilly and Company and Gan and Lee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Long-Acting Insulin Analogue, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Long-Acting Insulin Analogue, also provides the sales of main regions and countries. Of the upcoming market potential for Long-Acting Insulin Analogue, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Long-Acting Insulin Analogue sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-Acting Insulin Analogue market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Long-Acting Insulin Analogue sales, projected growth trends, production technology, application and end-user industry.
Long-Acting Insulin Analogue Segment by Company
Tonghua Dongbao Pharmaceutical
Sanofi
Novo Nordisk
The United Laboratories International Holdings
Eli Lilly and Company
Gan and Lee Pharmaceuticals
Long-Acting Insulin Analogue Segment by Type
Insulin Degludec
Insulin Detemir
Insulin Glargine
Long-Acting Insulin Analogue Segment by Application
Gestational Diabetes
Type 2 Diabetes
Type 1 Diabetes
Other Diabetes
Long-Acting Insulin Analogue Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-Acting Insulin Analogue market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-Acting Insulin Analogue and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-Acting Insulin Analogue.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Long-Acting Insulin Analogue market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Insulin Analogue manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-Acting Insulin Analogue in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Long-Acting Insulin Analogue in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Table of Contents
189 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Long-Acting Insulin Analogue Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Long-Acting Insulin Analogue Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Long-Acting Insulin Analogue Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Long-Acting Insulin Analogue Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Long-Acting Insulin Analogue Market Dynamics
- 2.1 Long-Acting Insulin Analogue Industry Trends
- 2.2 Long-Acting Insulin Analogue Industry Drivers
- 2.3 Long-Acting Insulin Analogue Industry Opportunities and Challenges
- 2.4 Long-Acting Insulin Analogue Industry Restraints
- 3 Long-Acting Insulin Analogue Market by Manufacturers
- 3.1 Global Long-Acting Insulin Analogue Revenue by Manufacturers (2020-2025)
- 3.2 Global Long-Acting Insulin Analogue Sales by Manufacturers (2020-2025)
- 3.3 Global Long-Acting Insulin Analogue Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Long-Acting Insulin Analogue Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Long-Acting Insulin Analogue Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Long-Acting Insulin Analogue Manufacturers, Product Type & Application
- 3.7 Global Long-Acting Insulin Analogue Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Long-Acting Insulin Analogue Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Long-Acting Insulin Analogue Players Market Share by Revenue in 2024
- 3.8.3 2024 Long-Acting Insulin Analogue Tier 1, Tier 2, and Tier 3
- 4 Long-Acting Insulin Analogue Market by Type
- 4.1 Long-Acting Insulin Analogue Type Introduction
- 4.1.1 Insulin Degludec
- 4.1.2 Insulin Detemir
- 4.1.3 Insulin Glargine
- 4.2 Global Long-Acting Insulin Analogue Sales by Type
- 4.2.1 Global Long-Acting Insulin Analogue Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Long-Acting Insulin Analogue Sales by Type (2020-2031)
- 4.2.3 Global Long-Acting Insulin Analogue Sales Market Share by Type (2020-2031)
- 4.3 Global Long-Acting Insulin Analogue Revenue by Type
- 4.3.1 Global Long-Acting Insulin Analogue Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Long-Acting Insulin Analogue Revenue by Type (2020-2031)
- 4.3.3 Global Long-Acting Insulin Analogue Revenue Market Share by Type (2020-2031)
- 5 Long-Acting Insulin Analogue Market by Application
- 5.1 Long-Acting Insulin Analogue Application Introduction
- 5.1.1 Gestational Diabetes
- 5.1.2 Type 2 Diabetes
- 5.1.3 Type 1 Diabetes
- 5.1.4 Other Diabetes
- 5.2 Global Long-Acting Insulin Analogue Sales by Application
- 5.2.1 Global Long-Acting Insulin Analogue Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Long-Acting Insulin Analogue Sales by Application (2020-2031)
- 5.2.3 Global Long-Acting Insulin Analogue Sales Market Share by Application (2020-2031)
- 5.3 Global Long-Acting Insulin Analogue Revenue by Application
- 5.3.1 Global Long-Acting Insulin Analogue Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Long-Acting Insulin Analogue Revenue by Application (2020-2031)
- 5.3.3 Global Long-Acting Insulin Analogue Revenue Market Share by Application (2020-2031)
- 6 Global Long-Acting Insulin Analogue Sales by Region
- 6.1 Global Long-Acting Insulin Analogue Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Long-Acting Insulin Analogue Sales by Region (2020-2031)
- 6.2.1 Global Long-Acting Insulin Analogue Sales by Region (2020-2025)
- 6.2.2 Global Long-Acting Insulin Analogue Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Long-Acting Insulin Analogue Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Long-Acting Insulin Analogue Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Long-Acting Insulin Analogue Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Long-Acting Insulin Analogue Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Long-Acting Insulin Analogue Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Long-Acting Insulin Analogue Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Long-Acting Insulin Analogue Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Long-Acting Insulin Analogue Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Long-Acting Insulin Analogue Revenue by Region
- 7.1 Global Long-Acting Insulin Analogue Revenue by Region
- 7.1.1 Global Long-Acting Insulin Analogue Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Long-Acting Insulin Analogue Revenue by Region (2020-2025)
- 7.1.3 Global Long-Acting Insulin Analogue Revenue by Region (2026-2031)
- 7.1.4 Global Long-Acting Insulin Analogue Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Long-Acting Insulin Analogue Revenue (2020-2031)
- 7.2.2 North America Long-Acting Insulin Analogue Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Long-Acting Insulin Analogue Revenue (2020-2031)
- 7.3.2 Europe Long-Acting Insulin Analogue Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Long-Acting Insulin Analogue Revenue (2020-2031)
- 7.4.2 Asia-Pacific Long-Acting Insulin Analogue Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Long-Acting Insulin Analogue Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Long-Acting Insulin Analogue Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Tonghua Dongbao Pharmaceutical
- 8.1.1 Tonghua Dongbao Pharmaceutical Comapny Information
- 8.1.2 Tonghua Dongbao Pharmaceutical Business Overview
- 8.1.3 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product Portfolio
- 8.1.5 Tonghua Dongbao Pharmaceutical Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Comapny Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Sanofi Long-Acting Insulin Analogue Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 Novo Nordisk
- 8.3.1 Novo Nordisk Comapny Information
- 8.3.2 Novo Nordisk Business Overview
- 8.3.3 Novo Nordisk Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Novo Nordisk Long-Acting Insulin Analogue Product Portfolio
- 8.3.5 Novo Nordisk Recent Developments
- 8.4 The United Laboratories International Holdings
- 8.4.1 The United Laboratories International Holdings Comapny Information
- 8.4.2 The United Laboratories International Holdings Business Overview
- 8.4.3 The United Laboratories International Holdings Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 The United Laboratories International Holdings Long-Acting Insulin Analogue Product Portfolio
- 8.4.5 The United Laboratories International Holdings Recent Developments
- 8.5 Eli Lilly and Company
- 8.5.1 Eli Lilly and Company Comapny Information
- 8.5.2 Eli Lilly and Company Business Overview
- 8.5.3 Eli Lilly and Company Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Eli Lilly and Company Long-Acting Insulin Analogue Product Portfolio
- 8.5.5 Eli Lilly and Company Recent Developments
- 8.6 Gan and Lee Pharmaceuticals
- 8.6.1 Gan and Lee Pharmaceuticals Comapny Information
- 8.6.2 Gan and Lee Pharmaceuticals Business Overview
- 8.6.3 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product Portfolio
- 8.6.5 Gan and Lee Pharmaceuticals Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Long-Acting Insulin Analogue Value Chain Analysis
- 9.1.1 Long-Acting Insulin Analogue Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Long-Acting Insulin Analogue Production Mode & Process
- 9.2 Long-Acting Insulin Analogue Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Long-Acting Insulin Analogue Distributors
- 9.2.3 Long-Acting Insulin Analogue Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
